Synergy Pharmaceuticals (SGYP) Receives Coverage Optimism Score of 0.16
Press coverage about Synergy Pharmaceuticals (NASDAQ:SGYP) has trended somewhat positive on Saturday, Accern reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.3368144293391 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Synergy Pharmaceuticals (SGYP) Stock: Bouncing Back From Yesterday’s Lows (cnafinance.com)
- Synergy Pharmaceuticals: Balancing Trust With Value – Seeking Alpha (seekingalpha.com)
- Synergy Pharmaceuticals, Inc. (SGYP) Receives Buy Rating from BTIG Research (americanbankingnews.com)
- ZYNE Shines, VBLT On Track, CALA Continues To Get Crushed (markets.businessinsider.com)
- General Electric, Synergy Pharma Stuck Again in Tuesday’s 52-Week Low Club (247wallst.com)
Shares of Synergy Pharmaceuticals (NASDAQ SGYP) traded down $0.05 during trading hours on Friday, reaching $1.95. 7,938,831 shares of the company’s stock traded hands, compared to its average volume of 5,938,308. The company has a current ratio of 4.26, a quick ratio of 3.88 and a debt-to-equity ratio of -68.13. Synergy Pharmaceuticals has a twelve month low of $1.68 and a twelve month high of $7.15.
Synergy Pharmaceuticals (NASDAQ:SGYP) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.06. The company had revenue of $5.01 million for the quarter, compared to the consensus estimate of $4.53 million. During the same quarter in the previous year, the business earned ($0.22) EPS. equities research analysts predict that Synergy Pharmaceuticals will post -1.06 EPS for the current fiscal year.
A number of equities analysts recently issued reports on the stock. HC Wainwright set a $8.00 price objective on shares of Synergy Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, October 18th. BTIG Research reissued a “buy” rating and issued a $7.00 price objective on shares of Synergy Pharmaceuticals in a report on Tuesday. CIBC dropped their price objective on shares of Synergy Pharmaceuticals from $9.00 to $6.00 and set an “outperform” rating on the stock in a report on Friday, September 8th. Citigroup Inc. reissued a “sell” rating and issued a $2.50 price objective (down previously from $3.20) on shares of Synergy Pharmaceuticals in a report on Wednesday, September 13th. Finally, Canaccord Genuity set a $13.00 price target on shares of Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Monday, July 31st. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. Synergy Pharmaceuticals has an average rating of “Hold” and an average target price of $8.02.
In other news, major shareholder Paulson & Co. Inc. sold 8,750,000 shares of Synergy Pharmaceuticals stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $2.82, for a total transaction of $24,675,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 3.80% of the company’s stock.
Synergy Pharmaceuticals Company Profile
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.